Sibel Yılmaz Öner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sibel Yılmaz Öner has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Bünyamin Kısacık
Department of Rheumatology, Sanko University Medical Faculty Hospital, 16049 Gaziantep, Turkey
2 shared publications - Cemal Bes
Department of Rheumatology, University of Health Sciences, Başakşehir Çam and Sakura City Hospital , Istanbul
2 shared publications - Emel Gönüllü
Department of Rheumatology, Sakarya Training and Research Hospital, Sakarya, Türkiye
2 shared publications - Gozde Yildirim Cetin
Department of Rheumatology, Kahramanmaras Sütçü İmam University Faculty of Medicine, Kahramanmaraş, Türkiye
2 shared publications - Mehmet Engin Tezcan
Department of Rheumatology, Kartal Dr. Lutfi Kirdar City Hospital, University of Health Sciences, Istanbul 34865, Turkey
2 shared publications - Nesrin Şen
Rheumatology Clinic, Kartal Dr. Lütfi Kırdar Training and Research Hospital, İstanbul, Turkey
2 shared publications
Latest Publications
- 24 August 2025
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
Illness perception as a determinant of medication adherence in adult Turkish patients with familial Mediterranean fever
Full Papers; Authors: S. Yilmaz-Oner, N. Sen, S. Acer Kasman, D. Sahin, N.N. Uzun, S. Osken, O. Volkan, C. Oner, M.E. Tezcan
- 24 August 2025
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
Illness perception as a determinant of medication adherence in adult Turkish patients with familial Mediterranean fever
Full Papers; Authors: S. Yilmaz-Oner, N. Sen, S. Acer Kasman, D. Sahin, N.N. Uzun, S. Osken, O. Volkan, C. Oner, M.E. Tezcan
- 1 March 2024
- Published by Galenos Yayinevi in Ulusal Romatoloji Dergisi
- Vol. 16 (1) , 15-24
Infection frequency may not increase in Familial Mediterranean fever
- 1 March 2024
- Published by Galenos Yayinevi in Ulusal Romatoloji Dergisi
- Vol. 16 (1) , 15-24
Infection frequency may not increase in Familial Mediterranean fever
- 6 March 2023
- Published by Springer Nature in Rheumatology International
- Vol. 43 (7) , 1313-1321
Importance of hematological markers in familial Mediterranean fever in terms of disease severity and amyloidosis
There are limited follow-up parameters for familial Mediterranean fever (FMF) related to disease severity and amyloidosis. Some hematological markers are emerging to assess inflammation. In this study, we hypothesized that some hematological parameters could be used to determine disease severity and amyloidosis in FMF. We included 274 adult FMF patients, and evaluated the relationship between neutrophil lymphocyte ratio (NLR), monocyte-lymphocyte ratio (MLR) and platelet-lymphocyte ratio (PLR), platelet counts and leukocyte counts, mean erythrocyte haemoglobin concentration (MCHC) and mean erythrocyte haemoglobin (MCH) with disease severity and amyloidosis. First, we classified patients according to disease severity and presence of amyloidosis. We then compared the parameters within the groups. In addition, we determined predictive cut-off values with ROC analysis. Finally, we correlated the change in ISSF scores with the change in hematological parameters of 52 patients with follow-up hematological indices after six months. The patients with severe-moderate group had higher CRP levels (p < 0.001), white blood cell (p = 0.002) and neutrophil counts (p = 0.004) and, conversely, lower MCHC levels (p = 0.001) than patients with mild disease severity. FMF patients with amyloidosis had higher neutrophil (p = 0.04) and monocyte count (p = 0.02), increased NLR (p = 0.01) and lower MLR (p = 0.02) levels than those without. In addition, MCHC levels were also lower in the severe-moderate group in the follow-up analyses after sixth months (p = 0.03). MCHC, neutrophil and monocyte counts, NLR, MLR may be associated with poor prognosis in FMF patients. These parameters can be used in conjunction with acute phase reactant and clinical features to assess disease status.
- 6 March 2023
- Published by Springer Nature in Rheumatology International
- Vol. 43 (7) , 1313-1321
Importance of hematological markers in familial Mediterranean fever in terms of disease severity and amyloidosis
There are limited follow-up parameters for familial Mediterranean fever (FMF) related to disease severity and amyloidosis. Some hematological markers are emerging to assess inflammation. In this study, we hypothesized that some hematological parameters could be used to determine disease severity and amyloidosis in FMF. We included 274 adult FMF patients, and evaluated the relationship between neutrophil lymphocyte ratio (NLR), monocyte-lymphocyte ratio (MLR) and platelet-lymphocyte ratio (PLR), platelet counts and leukocyte counts, mean erythrocyte haemoglobin concentration (MCHC) and mean erythrocyte haemoglobin (MCH) with disease severity and amyloidosis. First, we classified patients according to disease severity and presence of amyloidosis. We then compared the parameters within the groups. In addition, we determined predictive cut-off values with ROC analysis. Finally, we correlated the change in ISSF scores with the change in hematological parameters of 52 patients with follow-up hematological indices after six months. The patients with severe-moderate group had higher CRP levels (p < 0.001), white blood cell (p = 0.002) and neutrophil counts (p = 0.004) and, conversely, lower MCHC levels (p = 0.001) than patients with mild disease severity. FMF patients with amyloidosis had higher neutrophil (p = 0.04) and monocyte count (p = 0.02), increased NLR (p = 0.01) and lower MLR (p = 0.02) levels than those without. In addition, MCHC levels were also lower in the severe-moderate group in the follow-up analyses after sixth months (p = 0.03). MCHC, neutrophil and monocyte counts, NLR, MLR may be associated with poor prognosis in FMF patients. These parameters can be used in conjunction with acute phase reactant and clinical features to assess disease status.
- 9 August 2021
- Published by Springer Nature in Clinical Rheumatology
- Vol. 41 (1) , 177-186
Budd–Chiari syndrome in Behçet’s disease: a retrospective multicenter study
Objective To compare the clinical features, laboratory findings, and prognosis of Behçet’s disease (BD) patients with and without Budd–Chiari syndrome (BCS). Methods This multicenter retrospective study investigated 61 (M/F: 41/20) patients with BD, having coexistent BCS, and 169 (M/F:100/69) BD patients as the control group without BCS from 22 different centers of Turkey diagnosed between 1990 and 2017. Results Of the total 61 BD patients with BCS, the onset of the first symptom and the median age of diagnosis were earlier in contrast to BD patients without BCS (p = 0.005 and p = 0.007). Lower extremity deep vein and inferior vena cava (IVC) thrombosis were more common in patients with BCS (all; p < 0.01) compared to the control group. Mortality was significantly higher in BD-BCS patients with IVC thrombosis than in the controls (p = 0.004). Since most of the cases in our cohort had chronic and silent form of BCS, mortality rate was 14.8%, which was on the lower range of mortality rate reported in literature (14–47%). While all BD-BCS patients received immunosuppressive (IS) agents, only half of them received additional anticoagulant treatments. Among IS agents, interferon treatment was more frequently used in this cohort (19%), compared to other series reported in literature (2.3%). Conclusion To our knowledge, this is the largest series of BD patients with BCS. Our patients had earlier disease onset and diagnosis, higher frequency of IVC thrombosis, and higher mortality rate, compared to BD patients without BCS. Mortality was significantly higher in BD-BCS patients with IVC thrombosis compared to controls. Key Points • Mortality rate is higher in BD-associated BCS patients with IVC involvement. • Chronic and silent form of BD-associated BCS has a better prognosis. • The main treatment options are corticosteroids and immunosuppressive agents, whereas anticoagulant treatment remains controversial.
- 9 August 2021
- Published by Springer Nature in Clinical Rheumatology
- Vol. 41 (1) , 177-186
Budd–Chiari syndrome in Behçet’s disease: a retrospective multicenter study
Objective To compare the clinical features, laboratory findings, and prognosis of Behçet’s disease (BD) patients with and without Budd–Chiari syndrome (BCS). Methods This multicenter retrospective study investigated 61 (M/F: 41/20) patients with BD, having coexistent BCS, and 169 (M/F:100/69) BD patients as the control group without BCS from 22 different centers of Turkey diagnosed between 1990 and 2017. Results Of the total 61 BD patients with BCS, the onset of the first symptom and the median age of diagnosis were earlier in contrast to BD patients without BCS (p = 0.005 and p = 0.007). Lower extremity deep vein and inferior vena cava (IVC) thrombosis were more common in patients with BCS (all; p < 0.01) compared to the control group. Mortality was significantly higher in BD-BCS patients with IVC thrombosis than in the controls (p = 0.004). Since most of the cases in our cohort had chronic and silent form of BCS, mortality rate was 14.8%, which was on the lower range of mortality rate reported in literature (14–47%). While all BD-BCS patients received immunosuppressive (IS) agents, only half of them received additional anticoagulant treatments. Among IS agents, interferon treatment was more frequently used in this cohort (19%), compared to other series reported in literature (2.3%). Conclusion To our knowledge, this is the largest series of BD patients with BCS. Our patients had earlier disease onset and diagnosis, higher frequency of IVC thrombosis, and higher mortality rate, compared to BD patients without BCS. Mortality was significantly higher in BD-BCS patients with IVC thrombosis compared to controls. Key Points • Mortality rate is higher in BD-associated BCS patients with IVC involvement. • Chronic and silent form of BD-associated BCS has a better prognosis. • The main treatment options are corticosteroids and immunosuppressive agents, whereas anticoagulant treatment remains controversial.
- Open Access
- 3 September 2019
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 6 (1) , 1-6
Demographic, clinical, and laboratory features of Turkish patients with gouty arthritis: A prospective cohort study
Objective: We have conducted this study to evaluate clinical and laboratory findings and to gather and evaluate information that would be useful in clinical practice, such as demographics, joint involvement patterns, laboratory anomalies, treatments applied, and responses obtained in patients diagnosed with gout. Methods: In our study, the demographic, clinical, and laboratory characteristics of 94 patients diagnosed with gout were evaluated. The patients were re-evaluated with regard to their clinical and laboratory findings at the end of the 1st and 3rd months, their responses to the treatment were observed, and where necessary, new treatment adjustments were made. Results: Seventy-nine (84%) of the patients were men, and 15 (16%) were women. The ages of the patients ranged between 22 and 86 years with the average age being 57.5 years. The joint involvement during a gouty arthritis attack was most frequently observed in the 1st metatarsophalangeal joint (87.2%), followed by the ankle joint (26.9%), and the knee joint (23.7%). The joint involvement pattern was evaluated to reveal that the acute monoarticular arthritis was observed in 87 patients (93.5%), followed by acute oligoarticular arthritis coming in second in terms of frequency (26.9%). An average attack was determined to last 10.7 days, and the average number of attacks in a year was 2.69. In our study, the colchicine treatment in 24 of our patients, in whom it was determined during the admission and follow-up process that they have not had gouty arthritis attack in the past 3 months, was stopped. Five (20.8%) patients whose colchicine treatment was stopped later developed gouty arthritis attacks, and the colchicine treatment was restarted. On the other hand, 10 out of 38 patients (26.3%), who have either been continuing or had never been on colchicine treatment, were observed to experience a gouty arthritis attack during their 1st and 3rd month check-ups. Conclusion: In patients with gout, it is recommended that the related diseases, as well as the triggering factors (alcohol, drug use, and dietary effect), be determined, the necessary lifestyle changes be made, and the treatments started. Cite this article as: Özdem İnan Y, Alpay Kanıtez N, Çelik S, Yılmaz Öner S, Yılmazer B, Bes C. Demographic, clinical, and laboratory features of Turkish patients with gouty arthritis: A prospective cohort study. Eur J Rheumatol 2019; 6(1): 1-6.
- 3 September 2019
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 6 (1) , 1-6
Open AccessDemographic, clinical, and laboratory features of Turkish patients with gouty arthritis: A prospective cohort study
Objective: We have conducted this study to evaluate clinical and laboratory findings and to gather and evaluate information that would be useful in clinical practice, such as demographics, joint involvement patterns, laboratory anomalies, treatments applied, and responses obtained in patients diagnosed with gout. Methods: In our study, the demographic, clinical, and laboratory characteristics of 94 patients diagnosed with gout were evaluated. The patients were re-evaluated with regard to their clinical and laboratory findings at the end of the 1st and 3rd months, their responses to the treatment were observed, and where necessary, new treatment adjustments were made. Results: Seventy-nine (84%) of the patients were men, and 15 (16%) were women. The ages of the patients ranged between 22 and 86 years with the average age being 57.5 years. The joint involvement during a gouty arthritis attack was most frequently observed in the 1st metatarsophalangeal joint (87.2%), followed by the ankle joint (26.9%), and the knee joint (23.7%). The joint involvement pattern was evaluated to reveal that the acute monoarticular arthritis was observed in 87 patients (93.5%), followed by acute oligoarticular arthritis coming in second in terms of frequency (26.9%). An average attack was determined to last 10.7 days, and the average number of attacks in a year was 2.69. In our study, the colchicine treatment in 24 of our patients, in whom it was determined during the admission and follow-up process that they have not had gouty arthritis attack in the past 3 months, was stopped. Five (20.8%) patients whose colchicine treatment was stopped later developed gouty arthritis attacks, and the colchicine treatment was restarted. On the other hand, 10 out of 38 patients (26.3%), who have either been continuing or had never been on colchicine treatment, were observed to experience a gouty arthritis attack during their 1st and 3rd month check-ups. Conclusion: In patients with gout, it is recommended that the related diseases, as well as the triggering factors (alcohol, drug use, and dietary effect), be determined, the necessary lifestyle changes be made, and the treatments started. Cite this article as: Özdem İnan Y, Alpay Kanıtez N, Çelik S, Yılmaz Öner S, Yılmazer B, Bes C. Demographic, clinical, and laboratory features of Turkish patients with gouty arthritis: A prospective cohort study. Eur J Rheumatol 2019; 6(1): 1-6.
- Open Access
- 3 September 2019
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 6 (1) , 34-37
Exon 2: Is it the good police in familial mediterranean fever?
Objective: Familial Mediterranean fever (FMF) is the most common autoinflammatory disease. Most of the identified disease-causing mutations are located on exon 10. As the number of studies about the effect of the exonal location of the mutation and its phenotypic expression is limited, we aimed to investigate whether the exonic location of the Mediterranean fever (MEFV) mutation has an effect on the clinical manifestation in patients with FMF. Methods: Study population was derived from the main FMF registry that included 2246 patients from 15 different rheumatology clinics. We categorized the mutations according to their exon locations and retrieved the clinical and demographic information from the database. Results: Patients having the MEFV mutations on exon 2 or 10 (n:1526) were divided into three subgroups according to the location of the MEFV mutations: Group 1 (exon 2 mutations), Group 2 (exon 10 mutations), and Group 3 (both exon 2 and exon 10 mutations). Group 2 patients were of a significantly younger age at onset, and erysipel-like erythema, arthritis, amyloidosis, and a family history of FMF were more common in this group. Conclusion: Patients with FMF and exon 10 mutations show more severe clinical symptoms and outcome. Exon 2 mutations tend to have a better outcome. Cite this article as: Yaşar Bilge Ş, Solmaz D, Şenel S, Emmungil H, Kılıç L, Yılmaz Öner S, et al. Exon 2: Is it the good police in familial mediterranean fever? Eur J Rheumatol 2019; 6(1): 33-6.
- 3 September 2019
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 6 (1) , 34-37
Open AccessExon 2: Is it the good police in familial mediterranean fever?
Objective: Familial Mediterranean fever (FMF) is the most common autoinflammatory disease. Most of the identified disease-causing mutations are located on exon 10. As the number of studies about the effect of the exonal location of the mutation and its phenotypic expression is limited, we aimed to investigate whether the exonic location of the Mediterranean fever (MEFV) mutation has an effect on the clinical manifestation in patients with FMF. Methods: Study population was derived from the main FMF registry that included 2246 patients from 15 different rheumatology clinics. We categorized the mutations according to their exon locations and retrieved the clinical and demographic information from the database. Results: Patients having the MEFV mutations on exon 2 or 10 (n:1526) were divided into three subgroups according to the location of the MEFV mutations: Group 1 (exon 2 mutations), Group 2 (exon 10 mutations), and Group 3 (both exon 2 and exon 10 mutations). Group 2 patients were of a significantly younger age at onset, and erysipel-like erythema, arthritis, amyloidosis, and a family history of FMF were more common in this group. Conclusion: Patients with FMF and exon 10 mutations show more severe clinical symptoms and outcome. Exon 2 mutations tend to have a better outcome. Cite this article as: Yaşar Bilge Ş, Solmaz D, Şenel S, Emmungil H, Kılıç L, Yılmaz Öner S, et al. Exon 2: Is it the good police in familial mediterranean fever? Eur J Rheumatol 2019; 6(1): 33-6.
- 3 July 2019
- Published by Springer Nature in Clinical Rheumatology
- Vol. 38 (11) , 3033-3039
Predictors and the optimal duration of sustained remission in rheumatoid arthritis
To determine predictors and optimal duration of sustained remission (SR) in patients with rheumatoid arthritis (RA).
- 3 July 2019
- Published by Springer Nature in Clinical Rheumatology
- Vol. 38 (11) , 3033-3039
Predictors and the optimal duration of sustained remission in rheumatoid arthritis
To determine predictors and optimal duration of sustained remission (SR) in patients with rheumatoid arthritis (RA).
- 6 September 2016
- Published by Springer Nature in Zeitschrift für Rheumatologie
- Vol. 76 (10) , 913-919
Fatigue in systemic lupus erythematosus
The aim of the study was to determine which disease-related factors and non-disease features can explain the presence of systemic lupus erythematosus (SLE)-related fatigue in Turkish patients.
- 6 September 2016
- Published by Springer Nature in Zeitschrift für Rheumatologie
- Vol. 76 (10) , 913-919
Fatigue in systemic lupus erythematosus
The aim of the study was to determine which disease-related factors and non-disease features can explain the presence of systemic lupus erythematosus (SLE)-related fatigue in Turkish patients.